PC
ALLO icon

Pier Capital’s Allogene Therapeutics ALLO Stock Holding History

Pier Capital’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-262,832
Closed -$1.65M – 108
2022
Q4 		$1.65M Sell
262,832
-748
-0.3% -$6.92K 0.27% 93
2022
Q3 		$2.85M Sell
263,580
-476,976
-64% -$6.48M 0.49% 85
2022
Q2 		$8.44M Sell
740,556
-6,113
-0.8% -$54.3K 1.44% 18
2022
Q1 		$6.8M Buy
746,669
+451,701
+153% +$4.7M 0.87% 68
2021
Q4 		$4.4M Sell
294,968
-155,214
-34% -$2.74M 0.46% 93
2021
Q3 		$11.6M Buy
450,182
+171,354
+61% +$4.07M 1.2% 34
2021
Q2 		$7.27M Buy
278,828
+5,182
+2% +$148K 0.73% 83
2021
Q1 		$9.66M Buy
273,646
+121,575
+80% +$4.1M 0.92% 70
2020
Q4 		$3.84M Buy
152,071
+3,843
+3% +$125K 0.41% 98
2020
Q3 		$5.59M Buy
+148,228
New +$5.59M 0.82% 77

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Pier Capital's ALLO Position: Q1 2023 in Review

Pier Capital sold out of Allogene Therapeutics (ALLO) in Q1 2023, closing a stake of 262,832 shares — an estimated $1.65M sold.

Pier Capital first reported a position in ALLO in Q3 2020 and held it in 10 quarters. The position peaked at $11.6M in Q3 2021. 176 funds tracked by Wall St. Rank hold ALLO as of Q1 2023.

  • Pier Capital reported no remaining Allogene Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Pier Capital sold 262,832 Allogene Therapeutics shares in Q1 2023, an estimated $1.65M.
  • Pier Capital first reported a position in Allogene Therapeutics in Q3 2020 and held it in 10 quarters.
  • Pier Capital's Allogene Therapeutics position peaked at $11.6M in Q3 2021.
  • 176 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2023.

Based on Pier Capital's 13F filing for Q1 2023, filed 10 May 2023.